文献速递心境障碍

艾司氯胺酮鼻喷雾剂与喹硫平缓释剂在短期和长期疗效上的比较:ESCAPE-TRD随机IIIb期临床试验的敏感性分析

Efficacy of esketamine nasal spray over quetiapine extended release over the short and long term: sensitivity analyses of ESCAPE-TRD, a randomised phase IIIb clinical trial.
PubMed 文献 · Br J Psychiatry · 2024-12-02

ESCAPE-TRD是一项随机、开放标签、评估者盲法、活性对照的IIIb期试验,纳入676例难治性抑郁症患者,1:1随机接受灵活剂量艾司氯胺酮鼻喷雾剂或喹硫平缓释剂,同时继续使用正在进行的SSRI/SNRI。所有关于主要终点和关键次要终点的敏感性分析均支持艾司氯胺酮鼻喷雾剂优于喹硫平缓释剂,相对风险分别为1.462至1.737和1.417至1.838(均p<0.05)。

要点

  • 在难治性抑郁症患者中,所有敏感性分析均支持艾司氯胺酮鼻喷雾剂优于喹硫平缓释剂。
  • 主要终点敏感性分析的相对风险为1.462至1.737,关键次要终点为1.417至1.838(均p<0.05)。
  • 艾司氯胺酮鼻喷雾剂缩短了首次缓解和确认缓解的时间,风险比分别为1.711和1.658(均p<0.001)。

核心结论

  • 艾司氯胺酮鼻喷雾剂在所有预设的缓解和复发定义下均持续显示出对喹硫平缓释剂的显著优效性。
  • 敏感性分析支持ESCAPE-TRD主要分析的结论,并证明结果具有稳健性。

研究设计与样本

  • ESCAPE-TRD为随机、开放标签、评估者盲法、活性对照的IIIb期试验。
  • 患者为难治性抑郁症,即在一个重性抑郁发作中对两种或以上抗抑郁治疗无应答。
  • 患者按1:1随机接受灵活剂量的艾司氯胺酮鼻喷雾剂或喹硫平缓释剂,同时继续使用正在进行的选择性5-羟色胺再摄取抑制剂/5-羟色胺去甲肾上腺素再摄取抑制剂。
  • 共676例患者,其中336例随机至艾司氯胺酮鼻喷雾剂组,340例随机至喹硫平缓释剂组。

主要发现

  • 主要终点为第8周时蒙哥马利-Å斯伯格抑郁评定量表评分≤10;关键次要终点为第8周达到缓解后直至第32周保持无复发。
  • 主要终点的所有敏感性分析均支持艾司氯胺酮鼻喷雾剂优于喹硫平缓释剂,相对风险为1.462至1.737(均p<0.05)。
  • 关键次要终点的所有敏感性分析均支持艾司氯胺酮鼻喷雾剂优于喹硫平缓释剂,相对风险为1.417至1.838(均p<0.05)。
  • 艾司氯胺酮鼻喷雾剂缩短了首次缓解时间,风险比1.711(95%置信区间1.402,2.087),p<0.001。
  • 艾司氯胺酮鼻喷雾剂缩短了确认缓解时间,风险比1.658(95%置信区间1.337,2.055),p<0.001。

关键数值与推荐

  • 难治性抑郁症定义为在一个重性抑郁发作中对两种或以上抗抑郁治疗无应答。
  • 主要终点为第8周时蒙哥马利-Å斯伯格抑郁评定量表评分≤10。
  • 关键次要终点为第8周达到缓解后直至第32周保持无复发。
  • 敏感性分析通过基于时间点、阈值和量表改变缓解定义来进行。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In patients with treatment resistant depression (TRD), the ESCAPE-TRD study showed esketamine nasal spray was superior to quetiapine extended release. AIMS: To determine the robustness of the ESCAPE-TRD results and confirm the superiority of esketamine nasal spray over quetiapine extended release. METHOD: ESCAPE-TRD was a randomised, open-label, rater-blinded, active-controlled phase IIIb trial. Patients had TRD (i.e. non-response to two or more antidepressive treatments within a major depressive episode). Patients were randomised 1:1 to flexibly dosed esketamine nasal spray or quetiapine extended release, while continuing an ongoing selective serotonin reuptake inhibitor/serotonin norepinephrine reuptake inhibitor. The primary end-point was achieving a Montgomery-Åsberg Depression Rating Scale score of ≤10 at Week 8, while the key secondary end-point was remaining relapse free through Week 32 after achieving remission at Week 8. Sensitivity analyses were performed on these end-points by varying the definition of remission based on timepoint, threshold and scale. RESULTS: Of 676 patients, 336 were randomised to esketamine nasal spray and 340 to quetiapine extended release. All sensitivity analyses on the primary and key secondary end-point favoured esketamine nasal spray over quetiapine extended release, with relative risks ranging from 1.462 to 1.737 and from 1.417 to 1.838, respectively (all p < 0.05). Treatment with esketamine nasal spray shortened time to first and confirmed remission (hazard ratio: 1.711 [95% confidence interval 1.402, 2.087], p < 0.001; 1.658 [1.337, 2.055], p < 0.001). CONCLUSION: Esketamine nasal spray consistently demonstrated significant superiority over quetiapine extended release using all pre-specified definitions for remission and relapse. Sensitivity analyses supported the conclusions of the primary ESCAPE-TRD analysis and demonstrated robustness of the results.

来源:Br J Psychiatry,查看原文。版权归原作者所有。

引用

  1. Young AH, Llorca PM, Fagiolini A, et al. Efficacy of esketamine nasal spray over quetiapine extended release over the short and long term: sensitivity analyses of ESCAPE-TRD, a randomised phase IIIb clinical trial. Br J Psychiatry. 2024. PMID: 39618237. doi:10.1192/bjp.2024.124

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。